Rhode Island 2022 Regular Session

Rhode Island Senate Bill S2203

Introduced
2/8/22  
Refer
2/8/22  
Report Pass
5/12/22  
Engrossed
5/19/22  
Refer
5/20/22  
Report Pass
6/21/22  
Engrossed
6/23/22  
Engrossed
6/23/22  

Caption

Relating To Insurance

Impact

The introduction of S2203 will likely broaden access to critical healthcare services for children diagnosed with specific autoimmune neuropsychiatric disorders. By ensuring mandatory coverage, the bill aims to reduce the financial burden on families and health insurance carriers for these costly treatments. The stipulation that health plans must also extend such coverage when necessary services are unavailable within state lines ensures that children can seek treatment even when it requires out-of-state services. Furthermore, the requirement for a sunset clause in December 2025 implies that the effectiveness and economic implications of this mandate will need to be re-evaluated periodically.

Summary

Bill S2203 focuses on amending the General Laws related to insurance in the state of Rhode Island. The bill mandates that all group health insurance policies issued in the state shall provide coverage for pediatric autoimmune neuropsychiatric disorders related to streptococcal infections. This treatment includes care for pediatric acute onset neuropsychiatric syndrome, ensuring that affected children receive necessary medical interventions such as intravenous immunoglobin therapy. The implementation is designed to take effect from January 1, 2023, expanding healthcare options for predominantly young patients dealing with these serious conditions.

Sentiment

Overall sentiment regarding S2203 appears to be supportive among health advocacy groups, particularly those focused on childhood health. Proponents argue that the bill addresses a significant gap in treatment options for children suffering from these conditions, arguing for the essential nature of timely access to comprehensive healthcare. However, some stakeholders, particularly within the insurance community, may express concerns about the potential increased costs associated with mandating specific treatments across all policies, which could lead to broader insurance rate increases.

Contention

Notable points of contention regarding S2203 include potential concerns over its economic impact on health insurance providers, who argue that increasing mandated coverages can lead to higher premiums for policyholders. Additionally, there may be debate over ensuring the adequacy of training among healthcare providers in diagnosing and treating these complex disorders, as effective management requires a specific set of medical knowledge and coordination. The need for future cost-benefit analyses, as mandated by the bill, will be critical in monitoring its implications on the healthcare landscape in Rhode Island.

Companion Bills

No companion bills found.

Similar Bills

RI H5256

Accident And Sickness Insurance Policies

RI S0024

Accident And Sickness Insurance Policies

RI H8171

Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.

RI S2076

Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.

RI S0473

Extends coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome by removing the sunset date of December 31, 2025, and mandating such coverage.

RI H5625

Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.

RI H7503

Relating To Insurance

WV SB615

Requiring certain health insurance providers cover treatment for certain pediatric autoimmune neuropsychiatric disorders